Angelman Syndrome Foundation opener
  • Walk
  • Contact Registry
  • News
  • Blog
DOnate
  • What is Angelman Syndrome
    • Symptoms and Causes
    • Testing and Diagnosis
    • Genetics of AS
    • Photo Gallery
  • For Parents
    • Newly Diagnosed
    • Accomplishments of Individuals
    • Participate in Research Studies
    • Angelman Therapeutics
  • Research
    • ASF Funded Research
    • Call for Proposals
    • Clinical Trials
    • Research Studies
    • LADDER
    • Research Funding Philosophy
  • Make an Impact
    • ASF Cure Club
    • Ways To Donate
    • Fundraise
    • Committees & Groups
    • Send Encouragement
    • Shop & Support ASF
    • Volunteer Opportunities
  • Clinics
    • Find a Clinic
    • Clinic Patient Survey
    • For Clinicians
    • Jacob Pritzker Fellowship Program
    • FAQs
  • Resources
    • Search by Topic
    • Adult Resources
    • ASF Family Resource Team
    • ASF Family Fund
    • ASF Family Champions
    • Angelman Syndrome A to Z
    • ASF Podcast
    • Behavior Resources
    • Communication Resources
    • Counseling Services
    • Educational Webinars
    • Federal Resources
    • IEP Resources
    • International AS Resources
    • Medical Resources
    • Medical & Social Referrals
    • Seizures
    • Sibling Programs
    • State Resources
  • Events
    • ASF Walk
    • Conferences and Symposia
    • Bank of America Chicago Marathon
  • About
    • Contact ASF
    • Contact Registry
    • Our Partners
    • Board of Directors
    • Communication Advisory Committee
    • Financial Transparency
    • History of ASF and Angelman Syndrome
    • Medical Advisory Board
    • Parent Advisory Committee
    • Scientific Advisory Committee
    • Receive Texts & Emails
    • Privacy

articles and announcements

Categories: Protein Degradation

December 21, 2019

Validation of Arc and Ephexin5 as Novel Therapeutic Targets for the Treatment of Angelman Syndrome

$200,000 – 2-years While it has been appreciated for some time that loss-of-function mutations in the UBE3A gene are the primary causative factor for Angelman syndrome (AS), the precise mechanisms by which the loss of Ube3A in the nervous system […]

Read more

Recent Posts

  • Roche Clinical Trial of Rugonersen in Angelman Syndrome
  • ASF Opens Application for its Inaugural Jacob Pritzker Fellowship
  • Canadian Angelman Syndrome Society is now ASF Canada
  • GFAS Ukraine and ASF partner to Launch Clinic in Ukraine
  • AngelmanUK and ASF partner to launch clinics in the UK

Browse

  • What is Angelman Syndrome
  • For Parents
  • ASF Funded Research
  • Make an Impact
  • Events
  • About
  • Angelman Resources & Education
  • Contact Registry
  • News
Address Angelman Syndrome Foundation
3015 E. New York Street
Suite A2 #285
Aurora, IL 60504
Phone800.432.6435 Emailinfo@angelman.org

Connect

  • facebook
  • twitter
  • linkedin
  • instagram
  • pinterest
  • rss
  • youtube

The Mission

The mission of the Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research, and support for individuals with Angelman syndrome, their families and other concerned parties. We exist to give all of them a reason to smile, with the ultimate goal of finding a cure.

  • 4-star charity navigator logo
  • Combined Federal Campaign logo
  • Community Congress logo
Copyright © 2023 Angelman Syndrome Foundation. ALL Rights Reserved. | Site design: BRAND INSPIRATION, LLC